Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates strong financial metrics, including EPS growth and robust ROE, alongside strategic capital deployment in share buybacks and dividends. The Q&A session revealed confidence in guidance and growth in core businesses, despite some pressures in international markets. The company's proactive management of LTC risk and strategic digital investments further support a positive outlook. The lack of market cap data suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
Earned Premium Growth Over 5% (adjusted for transactions).
After-Tax Adjusted Operating Earnings $353 million, up nearly 10% year-over-year. The increase reflects strong execution across the business.
After-Tax Adjusted Operating EPS $2.14, up nearly 10% year-over-year. The increase reflects strong execution across the business.
U.S. Group Business Sales Up 22% year-over-year. Driven by strong persistency at 92% and premium growth of approximately 5%.
Total U.S. Group Earnings Over $220 million. Driven by record earnings in Group Life and strong performance in group disability business.
Unum US Before Tax Earnings $338 million with an ROE of 25%.
Colonial Life Adjusted Operating Income $127.8 million, up from $115.7 million in Q1 2025. Driven by strong benefits experience and premium growth.
Colonial Life Premium Income $472.7 million, up from $457.3 million in Q1 2025. Driven by strong sales in the prior year and stable persistency.
Unum International Adjusted Operating Income $30.9 million, down from $38.7 million in Q1 2025. Decline due to unfavorable experience in the U.K. business.
Unum UK Adjusted Operating Income GBP 20.4 million, down from GBP 29.5 million in Q1 2025. Decline due to larger average claim size in group long-term care disability business.
Unum US Group Disability Adjusted Operating Earnings $106.6 million, with a benefit ratio of 63.7% compared to 61.8% in Q1 2025. Reflects normalization and stable incidents.
Unum US Group Life and AD&D Adjusted Operating Income $115.1 million, up from $69.2 million in Q1 2025. Benefit ratio decreased to 61.8% from 69.3% due to lower incidents.
Unum US Supplemental and Voluntary Lines Adjusted Operating Earnings $116.2 million, down from $140.7 million in Q1 2025. Decline due to unfavorable underlying experience and last year's long-term care transaction.
Unum International Premium Growth 8.1%, supported by healthy persistency levels and sales growth of 5.5%.
Colonial Life Sales $106.3 million, slightly up from the prior year.
Group Persistency 92%, increased 2.7% year-over-year.
Capital Position (RBC) 460%, over 100 points above target range.
Holding Company Liquidity Approximately $1.7 billion.
Share Repurchases Approximately $400 million in Q1 2026, reducing public float by 3%.
Common Stock Dividend $78.4 million in Q1 2026.
Digital-first Total Leave platform: This platform, combined with traditional insurance products and technologies like HR Connect, delivers a best-in-class experience to clients, contributing to high satisfaction and persistency.
Supplemental and voluntary product business: These lines saw a 20% sales growth in the quarter, leveraging digital tools to meet broader employer benefit needs.
U.S. group business: Sales increased by 22%, with persistency at 92%, driving premiums up approximately 5%.
Colonial Life: Achieved record earnings supported by premium growth, attractive returns, and strong relationships in the worksite market.
Unum International: Mixed results with strong growth in Poland offset by benefits pressure in the U.K. Premiums grew 8.1%, with Poland growing 15.2% and the U.K. growing 6.5%.
Capital deployment: Repurchased approximately $400 million of shares, reducing public float by 3% in one quarter. Paid $78 million in dividends and plans to increase dividend rate.
Closed Block management: Reduced exposure by 7% of group LTC cases, achieved with clarity and transparency for clients. Fairwind protection remains at $2.2 billion.
Technology investments: Deliberate investments in technology-enabled solutions to win, retain, and grow business by improving employer and employee engagement with benefits.
Leadership transition: Tim Arnold, a long-serving leader, will retire in July, with Steve Jones appointed as the next President of Colonial Life, ensuring continuity and long-term growth.
Unum International Performance: Mixed results were reported, with strong growth in Poland offset by benefit pressures in the U.K. The U.K. business faced unfavorable claims performance, including a larger average claim size in group long-term care disability, which could impact profitability.
Paid Family and Medical Leave (PFML): Higher incidents in short-term disability product lines, particularly in newer PFML states, led to modest pressure on results. This reflects the challenges of operating in a maturing market with evolving regulatory and market dynamics.
Closed Block Management: The company faces ongoing challenges in managing its Closed Block, including exposure to long-term care (LTC) risks. While progress has been made in reducing exposure, the block still presents accounting volatility and tail risk. Additionally, the alternative investment portfolio supporting LTC underperformed expectations in Q1.
Group Disability Business: Higher incidents in short-term disability products and elevated claims in certain areas could pose risks to profitability if trends persist.
Capital Deployment: While the company has a strong capital position, the accelerated share repurchase program could limit flexibility for future investments or unforeseen challenges.
Revenue Growth: The company expects to deliver 4% to 7% top-line growth for 2026.
Earnings Per Share (EPS) Growth: The company projects 8% to 12% EPS growth for 2026.
Return on Equity (ROE): The company anticipates attractive returns on equity in its core operations for 2026.
Capital Deployment: The company plans to redeploy approximately $1.3 billion in 2026, which aligns with its annual capital generation. This includes $1 billion in share repurchases and increased dividend payouts.
Premium Growth: Core premium growth is expected to accelerate throughout 2026, targeting a full-year growth rate of 4% to 7%.
Group Life and AD&D Benefit Ratio: The company expects moderate outperformance in the Group Life and AD&D benefit ratio, averaging in the mid- to high-60% range.
Persistency: Persistency levels are expected to remain strong, with total group persistency at 92%.
International Business: The company is optimistic about long-term value growth in its international businesses, despite mixed results in the first quarter of 2026.
Closed Block Management: The company plans to continue reducing its exposure and tail risk in the Closed Block through deliberate actions, including risk transfer and case closures.
Capital Metrics: The company aims to maintain robust capital metrics, including a Risk-Based Capital (RBC) ratio of 400% to 425% and holding company liquidity of $2 billion to $2.5 billion by year-end 2026.
Dividend Payout: $78 million paid out in dividends during the first quarter of 2026.
Future Dividend Plans: The company plans to increase its dividend rate in the coming months, heading into the annual meeting.
Share Repurchase: Approximately $400 million worth of shares repurchased in the first quarter of 2026, reducing the public float by approximately 3%.
Annual Share Repurchase Plan: The company remains on track to repurchase $1 billion worth of stock in 2026, representing all of the free cash flow planned to be generated.
The earnings call summary indicates strong financial metrics, including EPS growth and robust ROE, alongside strategic capital deployment in share buybacks and dividends. The Q&A session revealed confidence in guidance and growth in core businesses, despite some pressures in international markets. The company's proactive management of LTC risk and strategic digital investments further support a positive outlook. The lack of market cap data suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
The earnings call summary and Q&A indicate strong financial metrics, optimistic guidance, and strategic initiatives like LTC derisking and capital management. Management's positive outlook on AI impact and competitive positioning in the disability market further supports a positive sentiment. The company's robust shareholder return plan and strategic growth initiatives suggest a stock price increase in the short term.
The earnings call summary and Q&A session reflect a mixed picture. Financial performance and guidance show stability with slight optimism, but there are concerns about morbidity and mortality assumptions and statutory reserving impacts. The Q&A reveals management's cautious approach and some uncertainties, particularly around capital deployment and reserve impacts. Without significant positive catalysts or strong negative indicators, the sentiment remains neutral, suggesting minimal stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.